BiPAP呼吸机对慢性阻塞性肺疾病Ⅱ型呼吸衰竭急性加重期疗效观察

为了探索不需建立人工气道的BiPAP呼吸机对慢性阻塞性肺疾病(COPD)呼吸衰竭急性加重期的病人近期疗效。作者对COPD呼吸衰竭急性加重期18例病人在控制性氧疗等治疗基础上应用BiPAP呼吸机作压力支持辅助通气治疗。结果表明应用本法12小时后(8小时/天),患者的动血二氧化碳分压(PaCO_2)有明显降低,并可维持控制性氧疗的血氧水平。现将结果报告如下。     

慢性阻塞性肺疾病急性加重对患者生活质量的影响

目的:探讨慢性阻塞性肺疾病急性加重对患者生活质量的影响。方法:以中国中医科学院广安门医院呼吸科长期慢病管理计划中确诊的慢性阻塞性肺疾病患者为研究对象,记录其在2013年1月至12月间发生的慢性阻塞性肺疾病急性加重事件的情况,并采用面对面访谈式问卷调查方法,在2013年12月对患者进行肺疾病评估测试、焦虑自评量表评分及抑郁自评量表评分,以探讨急性加重发生对患者健康的影响。结果:504例慢性阻塞性肺疾病患者中,过去1年间220例(43.7%)有急性加重发作,其CAT评分、SAS评分、SDS评分均高于未发生急性加重患者,差异均有统计学意义(P0.05)。急性加重发作患者中,66.4%的生活质量均受到中等程度及以上影响,高于无急性加重发生组(52.1%),差异有统计学意义(P0.05)。此外,有急性加重发作的患者合并焦虑和/或抑郁状态的患病率也高于无急性加重发作的患者,差异有统计学意义(P0.05)。结论:慢性阻塞性肺疾病急性加重对患者生活质量、精神状态均可能产生不利影响。     

慢性阻塞性肺疾病急性加重患者下呼吸道病原菌分析

目的了解慢性阻塞性肺疾病急性加重患者（AECOPD）下呼吸道感染病原菌的特点及耐药情况,为临床合理选择抗菌药物提供借鉴。方法取诸暨市人民医院2005年1月至2009年12月住院的273例AECOPD患者的下呼吸道痰标本及纤支镜刷取分泌物进行培养、鉴定、药敏,并对结果进行分析。结果273例AECOPD患者中有225例患者分离到病原菌,分离病原菌282株。病原菌中革兰阴性杆菌最多,占46．8％,依次为铜绿假单胞菌、肺炎克雷伯菌、鲍曼不动杆菌等;革兰阳性球菌占18．4％,以金黄色葡萄球菌最多,肠球菌、肺炎链球菌次之;真菌占20．9％;流感嗜血杆菌占13．8％。药敏结果显示阴性杆菌对美罗培意敏感率最好,其次为亚胺培南、哌拉西林．他唑巴坦。结论AECOPD患者下呼吸道病原菌以革兰阴性杆菌为主,耐药现象明显,流感嗜血杆菌已经成为AECOPD患者重要的致病菌之一。     

营养支持对慢性阻塞性肺疾病急性加重期患者预后影响

目的：评价营养支持对慢性阻塞性肺疾病急性加重期患者预后影响分析。方法：选取2015年3月—2017年3月期间重庆市巴南区第二人民医院呼吸内科收治慢性阻塞性肺疾病急性加重期患者110例纳入研究,按照随机数字表分为干预组（55例）和常规组（55例）,两组患者入院后常规治疗,包括抗感染、低流量吸氧以及支气管舒张等,干预组在此基础上进行营养支持干预,观察周期为1年,随访两组患者的肺功能、血气分析指标、免疫指标、住院时间以及病死率等相关指标变化。结果：观察结束后,干预组患者的肺功能、血气分析指标、免疫功能显著高于对照组（P＜0.05）,住院时间以及病死率显著低于对照组（P＜0.05）。结论：科学合理的营养支持干预可有效改善慢性阻塞性肺疾病急性加重期患者的肺功能和免疫功能,降低其住院时间和病死率,可作为改善患者预后以及延缓其病情进展速度的一种有效干预措施。     

急诊慢性阻塞性肺疾病急性加重期患者预后相关因素分析

目的:探讨急诊收治的慢性阻塞性肺疾病急性加重期患者的预后相关因素。方法:选取我院2008年12月-2013年12月急诊收治的慢性阻塞性肺疾病急性加重期患者94例,根据预后结果分为死亡组17例及存活组77例,回顾分析两组患者的相关资料。结果:存活组较死亡组BMI、血肌酐值、清蛋白、pH值、PaCO2、FT3差异具有统计学意义。死亡组较存活组在APACHEⅡ,CCS,有创通气率及合并肺心病率上差异均具有统计学意义。结果显示合并肺心病率、APACHEⅡ评分、肌酐、清蛋白为影响慢性阻塞性肺疾病急性加重期患者预后的独立因素。结论:急诊收治的慢性阻塞性肺疾病急性加重期患者如合并肺心病率,APACHEⅡ评分较高,血肌酐较高,清蛋白较低,这些因素提示我们患者预后较差,需及早进行相关治疗。     

辛伐他汀对慢性阻塞性肺疾病急性加重期患者凝血功能的影响研究

摘要 目的：探讨辛伐他汀对慢性阻塞性肺疾病急性加重期（chronic obstructive pulmonary acute exacerbation,AECOPD）患者凝血功能的影响。方法：选取2019年8月~2020年8月我科住院治疗的80例AECOPD患者作为本次研究对象,随机性分为对照组和观察组,每组分别40例。对照组给予常规治疗措施,观察组在对照组的治疗基础上另予辛伐他汀口服。比较两组患者刚入院时、治疗10 d后、30 d后的凝血功能指标、呼吸机使用时间、住院时间及治疗费用。治疗30天后所有患者按照肺功能损害严重程度分级,比较各级患者的凝血功能指标。结果：治疗后10 d和30 d,观察组患者的D-二聚体（D-dimer,DD）、同型半胱氨酸（homocysteine,HCY）及纤维蛋白原（fibrinogen,FBG）水平均明显减低,凝血酶时间（thrombin time,TT）明显缩短,凝血酶原时间（prothrombin time,PT）及活化部分凝血酶时间（activation of partial thrombin time,APTT）明显变长,各项指标与对照组相比较具有统计学意义（P<0.05）。观察组呼吸机使用时长及住院天数均明显低于对照组,治疗费用也明显低于对照组,其差异具有统计学意义（P<0.05）。治疗30天后按照肺功能中度损害患者的DD、HCY、FBG水平均显著低于重度和极重度患者,TT显著短于重度和极重度患者,PT和APTT显著长于重度和极重度患者（P<0.05）;重度肺功能损害患者的DD、HCY、FBG水平均显著低于极重度患者,TT显著短于极重度患者,PT和APTT显著长于极重度患者（P<0.05）。结论：辛伐他汀能够明显改善AECOPD患者的凝血功能,缩短住院时间,慢阻肺患者肺功能损害程度与其凝血功能异常程度存有一定关联性,肺功能损害程度较重者其凝血功能异常更为明显。     

布地奈德联合沙丁胺醇治疗慢性阻塞性肺疾病急性加重期疗效观察

目的观察布地奈德联合沙丁胺醇雾化吸入治疗慢性阻塞性肺疾病急性加重期的临床疗效。方法将我院收治的60例慢性阻塞性肺疾病急性加重期患者随机分为治疗组30例,应用布地奈德混悬液和沙丁胺醇溶液雾化吸入,疗程7天;对照组30例给予沙丁胺醇溶液雾化吸入,疗程7天。疗程结束观察患者第1s用力呼气容积(FEV1)占预计值百分比(FEV1%)和第1s用力呼气容积与用力肺活量比值(FEV1/FVC)。结果治疗组治疗后FEV1%、FEV1/FVC明显升高,与治疗前比较,差异有统计学意义(P<0.05);对照组治疗后,FEV1占预计值百分比及FEV1/FVC均有明显升高(P<0.05),但改善情况不如治疗组。两组治疗前后空腹血糖、电解质均无明显变化。结论沙丁胺醇、布地奈德联合雾化吸入治疗慢性阻塞性肺疾病急性加重期的疗效显著,且副作用小,给药方便,值得推广。     

双水平气道内正压通气治疗慢性阻塞性肺疾病急性发作并Ⅱ型呼吸衰竭的临床疗效观察

摘要目的：观察双水平气道正压通气（bilevelpositiveairwaypressure,BiPAP）呼吸机治疗慢性阻塞性肺疾病急性加重期（acuteex—acerlationofchronicobstructivepulmonarydisease,AECOPD）合并Ⅱ型呼吸衰竭的临床疗效。方法：148例经诊断为AEc0PD合并II型呼吸衰竭的患者,按照入院的先后顺序随机分为对照组及治疗组,每组74例;对照组患者给予抗感染、祛痰、平喘、吸氧等常规治疗;治疗组在上述治疗的基础上,给予BiPAP呼吸机治疗,8h／天,分析治疗前两组患者的基线资料及生命体征,抽取治疗前及治疗后24h、72h股动脉血液进行动脉血气分析（包括pH、PaCO2、PaO2、Sa02等）,并比较两组患者的住院天数。结果：治疗前两组患者的基线资料及生命体征指标无显著性差异（P〉0．05）;两组患者治疗后pH、PaCO2、PaO2、SaO2均较治疗前有所改善（P〈0．05或P〈0．01）;与对照组比较,治疗组pH、P02、PC02、Sa02的改善情况显著优于对照组（P〈0．05）,且患者的住院天数显著缩短（P〈0．05）。结论：采用BiPAP呼吸机辅助治疗AECOPD合并II型呼衰的患者疗效较常规治疗更好,安全可靠,值得临床推广应用。     

无创正压通气治疗慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭的临床效果

目的:探讨无创正压通气(Non-vasive Pressure Present Ventilation,NIPPV)对慢性阻塞性肺疾病(Chronic Obstructive Pulmonary Diseases,COPD)合并Ⅱ型呼吸衰竭(TypeⅡrespiratory failure)患者肺功能及动脉血气分析的影响。方法:选择2013年8月-2015年8月在我院接受治疗的慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭患者100例,根据治疗方法不同,将所选研究对象分为研究组及对照组,每组50例。对照组患者实施鼻导管吸氧,研究组患者采用无创正压通气治疗。观察并比较两组患者治疗前后的动脉血气分析结果、肺功能指标的变化情况以及临床疗效。结果:与治疗前比较,两组患者治疗后FEV1/FVC,FEV1及MVV均升高,且研究组高于对照组,差异均具有统计学意义(P0.05)。治疗后,两组患者p H及PaO_2均较治疗前明显上升,PaCO_2则明显下降,差异具有统计学意义(P0.05);治疗后,研究组pH及PaO_2高于对照组,而PaCO_2低于对照组,差异具有统计学意义(P0.05)。研究组总有效率(92.5%)显著高于对照组(75.6%),差异具有统计学意义(P0.05)。结论:无创正压通气能够改善慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭患者的肺功能及动脉血气分析结果,具有显著的临床疗效,值得进一步推广应用。     

慢性阻塞性肺疾病急性加重期合并侵袭性肺曲霉菌病23例临床分析

目的探讨慢性阻塞性肺疾病急性加重期(AECOPD)合并侵袭性肺曲霉菌病(IPA)的危险因素及临床特点。方法回顾分析2008年5月至2010年6月浙江大学医学院附属第一医院收治的慢性阻塞性肺疾病急性加重期合并侵袭性肺曲霉菌病患者的临床资料。结果 23例患者中,确诊7例,临床诊断16例。平均年龄(68.3±4.32)岁。其中22例使用广谱抗生素和15例长期使用激素,12例1年内住院>3次,11例年龄>70岁。病灶出现在双上肺占52.1%,双肺多发占21.7%,双下肺占13.0%,位于右中叶和左舌叶共占13.0%;其中5例(21.7%)出现晕征,4例(17.3%)出现"新月"征。结论使用广谱抗生素、长期激素治疗、频繁住院等是慢性阻塞性肺疾病合并肺曲霉菌的危险因素,患者临床表现缺乏特异性,胸部CT表现有一定特征性,结合患者有危险因素及实验室检查,有助于早期诊断和早期治疗,改善患者预后。     

慢性阻塞性肺疾病急性加重期病原菌与其综合评估分级间关系的研究

目的研究慢性阻塞性肺疾病急性加重期（AEC0PD）病原菌分布及耐药情况,与其综合评估分级之间的关系。方法对2008年1月至2012年6月金华市第五医院住院142例AEC0PD患者的痰标本进行细菌培养和药物敏感试验;所有患者按慢性阻塞性肺疾病全球倡仪（GOLD）20U版的要求进行综合评估后分级为A级、B级、C级、D级。结果142例AEC0PD患者有99例患者分离到病原菌,共129株。其中,革兰阴性菌最多,占59.6%,依次为铜绿假单胞菌、肺炎克雷伯菌、鲍曼不动杆菌、大肠埃希菌,体外药敏结果显示大部分革兰阴性菌对亚胺培南有较好敏感性（72% ）;革兰阳性菌占20. 9%,依次为金黄色葡萄球菌、肠球菌、肺炎链球菌,大部分革兰阳性菌对万古霉素有较好敏感性（85% ）;真菌占19. 3% ,分别为A色念珠菌、热带念珠菌等,对氟胞嘧啶、两性霉素、伊曲康唑、伏立康唑等敏感度高。混合感染占总患者的27.2%。A、B、C和D级AEC0PD患者,病原菌为革兰阴性菌的分别占46.6% ,50.0% ,59. 0%和66.0% ;真菌分别为6. 2%、12. 5%、20. 4%和24. 0% ;混合感染患者分别为15. 3%、23.0%、22. 9%和36. 8%。C级、D级患者革兰阴性菌和真菌检出率,混合感染率较A级、B级高（P 〈 0. 05 ）。结论AEC0PD患者病原菌以革兰阴性菌为主,真菌感染、混合感染率亦较髙,病原菌耐药现象严重,患者综合评估分级高。     

急性加重期慢性阻塞性肺疾病患者痰色评分与肺部微生物和病情严重程度的相关性CSCD

目的 探讨急性加重期慢性阻塞性肺疾病患者痰色评分与肺部微生物、病情严重程度的相关性。方法 选择2018年3月至2019年9月我院收治的122例急性加重期慢性阻塞性肺疾病患者,根据其痰色评分分为1~2分组(n=30)与3~4分组(n=92),比较两组患者肺部微生物分布、病情严重程度分布、慢性阻塞性肺疾病评估测试(CAT)评分、白细胞(WBC)水平、C反应蛋白(CRP)水平,分析急性加重期慢性阻塞性肺疾病患者痰色评分与肺部微生物、病情严重程度的相关性。结果 3~4分组患者肺部肺炎克雷伯菌、铜绿假单胞菌、金黄色葡萄球菌、肺炎链球菌、草绿色链球菌、白假丝酵母、酵母样真菌、丝状真菌检出率与1~2分组比较差异无统计学意义(均P>0.05)。3~4分组患者鲍曼不动杆菌检出率显著高于1~2分组(P<0.05)。3~4分组患者病情严重程度分布与1~2分组比较差异有统计学意义(P<0.05)。3~4分组患者CAT评分、WBC水平、CRP水平均显著高于1~2分组(均P<0.05)。急性加重期慢性阻塞性肺疾病患者痰色评分与肺炎克雷伯菌、铜绿假单胞菌、金黄色葡萄球菌、肺炎链球菌、草绿色链球菌、白假丝酵母、酵母样真菌、丝状真菌检出率无显著相关性(均P>0.05),而与鲍曼不动杆菌检出率、CAT评分、WBC水平、CRP水平、病情严重程度呈显著相关性(均P<0.05)。结论 痰色评分与急性加重期慢性阻塞性肺疾病患者肺部微生物和病情严重程度关系密切,有望成为临床评价该类患者肺部微生物分布及病情严重程度的方法之一。     

Alterations of plasma inflammatory biomarkers in the healthy and chronic obstructive pulmonary disease patients with or without acute exacerbation

Chronic obstructive pulmonary disease (COPD) is one of the leading causes of mortally and morbidity, associated with acute exacerbations (AECOPD) resulted from smoking, infection or air pollution. Systemic inflammation has been considered as one of major pathophysiologic alterations in AECOPD. The present study aimed at developing disease-specific biomarker evaluation by integrating proteomic profiles of inflammatory mediators in AECOPD with clinical and biological informatics. Plasma samples from 18 subjects including healthy people or patients with stable COPD or AECOPD were collected to measure 507 inflammatory mediators using antibody microarray. Clinical informatics was achieved by a Digital Evaluation Score System (DESS) for assessing severity of patients. 20 mediators were significantly different between 3 groups (p<0.05), of which, Cerberus 1, Growth Hormone R, IL-1F6, IL-17B R, IL-17D, IL-19, Lymphotoxin beta, MMP-10, Thrombopoietin and TLR4 were correlated with DESS scores (p<0.05). There was a down-regulation of systemic inflammatory responses in AECOPD. The integration of proteomic profile with clinical informatics as part of clinical bioinformatics is important to screen disease-specific and disease-staged biomarkers. This article is part of a Special Issue entitled: Proteomics: The clinical link.     

Circadian-rhythm differences among emergency department patients with chronic obstructive pulmonary disease exacerbation

The purpose of the study was determine whether patients with chronic obstructive pulmonary disease (COPD) exacerbation who present to the emergency department (ED) during the night (00:00 to 07:59 h) vs. other times of the day have more severe COPD exacerbation, require more intensive treatment, and have worse clinical outcomes. A multicenter cohort study was completed involving 29 EDs in the United States and Canada. Using a standard protocol, consecutive ED patients with COPD exacerbation were interviewed, and their charts were reviewed. Of 582 patients enrolled, 52% were women, and the median age was 71 yrs (interquartile range, 64-77 yrs). Nighttime patients (15% of cohort) did not differ from patients presenting at other times except that they were less likely to have private insurance, more likely to have a history of corticosteroid use, and have a shorter duration of symptoms exacerbation. Except for a few features indicative of more severe COPD exacerbation (such as higher respiratory rate at ED presentation, greater likelihood of receiving noninvasive positive pressure ventilation, and increased risk of endotracheal intubation), nighttime patients did not differ from other patients with respect to ED management. Nighttime patients were approximately three-fold more likely to be intubated in the ED (odds ratio, 3.46; 95% confidence interval, 1.10-10.9). There were no day-night differences regarding ED disposition and post-ED relapse. Except for some features indicating more severe exacerbation, nighttime ED patients had similar chronic COPD characteristics, received similar treatments in the ED, and had similar clinical outcomes compared with patients presenting to the ED at other times of the day.     

慢性阻塞性肺疾病急性加重期病原学及细菌药性分析

目的:探讨慢性阻塞性肺疾病急性加重期病原学特点及细菌耐药情况,为临床合理使用抗生素提供科学依据。方法:回顾性分析我院呼吸内科和老年学科2008年1月-2009年1月563例慢性阻塞性肺疾病(急性加重期)住院患者痰培养及药敏试验结果。结果:563例患者中检出阳性结果205例,检出率为36.41%。其中G+菌46例、G-菌119例、真菌40例。G+菌以金黄色葡萄球菌最多(14例),其次为表皮葡萄球菌和草绿色链球菌;G-菌以铜绿假单胞菌最多(37例),其次为克雷伯菌;真菌以白色念珠菌最多(20例)。G-杆菌对氨苄西林、哌拉西林、头孢唑啉、复方新诺明耐药严重,对亚胺培南、含β-内酰胺酶抑制剂的联合制剂较敏感。金黄色葡萄球菌对多种抗生素严重耐药,对万古霉素、亚胺培南较敏感。真菌对氟康唑敏感占50.81%,对伊曲康唑敏感占30.12%,对酮康唑敏感占30.83%,对5-氟胞嘧啶敏感占10.74%。结论:慢性阻塞性肺疾病急性加重期以G-为主,真菌感染有增多趋势,病原菌呈现多重耐药现象。     

经鼻面罩BiPAP正压通气治疗重症支气管哮喘合并Ⅱ型呼吸衰竭的临床观察

目的观察经鼻面罩BiPAP无创正压通气治疗重症支气管哮喘合并Ⅱ型呼吸衰竭的临床效果。方法观察患者行呼吸机治疗前,治疗后4、12、24、48h的临床症状及血气分析。结果治疗后患者的临床症状、血气分析（pH、PaCO2、PaO2）均有显著改善,且无严重并发症发生。结论 BiPAP无创正压通气有助于呼吸改善,正确有效的护理措施对保证通气治疗的效果、减少并发症具有重要意义。     

Prognostic and diagnostic significance of mid-regional pro-atrial natriuretic peptide in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure: data from the ACE 2 Study

Abstract

Purpose: To compare the diagnostic and prognostic value of mid-regional pro-ANP (MR-proANP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with acute dyspnea.

Methods: MR-proANP and NT-proBNP were measured with commercial immunoassays at hospital admission (n?=?313), on day 2 (n?=?234), and before discharge (n?=?91) and compared for diagnosing acute heart failure (HF; n?=?143) and to predict mortality among patients with acute HF and acute exacerbation of chronic obstructive pulmonary disease (AECOPD; n?=?84) separately.

Results: The correlation coefficient between MR-proANP and NT-proBNP was 0.89 (p?<?0.001) and the receiver-operating area under the curve (AUC) was 0.85 (95% CI 0.81–0.89) for MR-proANP and 0.86 (0.82–0.90) for NT-proBNP to diagnose acute HF. During a median follow-up of 816?days, mortality rates were 46% in acute HF patients and 42% in AECOPD patients. After adjustment for other risk variables by multivariate Cox regression analysis, MR-proANP and NT-proBNP concentrations were associated with mortality in patients with acute HF, but only MR-proANP were associated with mortality among patients with AECOPD: hazard ratio (_lnMR-proANP) 1.98 (95% CI 1.17–3.34).

Conclusion: MR-proANP and NT-proBNP concentrations provide similar diagnostic and prognostic information in patients with acute HF. In contrast to NT-proBNP, MR-proANP measurements also provided independent prognostic information in AECOPD patients.     

Prevalence and risk of viral infection in patients with acute exacerbation of chronic obstructive pulmonary disease: a meta-analysis

Exacerbations of chronic obstructive pulmonary disease (COPD) lead to substantial morbidity and mortality. Viral infections could be an important cause of acute exacerbations of COPD (AECOPD) and only a few studies report the prevalence of respiratory viruses on this disease. We aimed to update the review on the prevalence of respiratory viral infection in patients with AECOPD with a meta-analysis. We reviewed the prevalence of respiratory viruses on this disease by searching PubMed systematically to identify primary studies published from Jan 1990 to March 2012. Studies met with seven criteria were extracted for meta-analysis. A total of 17 studies were eligible for the meta-analysis. Weighted overall prevalence of respiratory viruses in patients with AECOPD was 39.3 % (95 % CI 36.9–41.6) with a high degree of a heterogeneity (I ² > 75 %). In contrast, the rate in stable COPD patients from four studies was 13.6 % (95 % CI 9.0–18.2) without any apparent heterogeneity. Pooled risk ratio for respiratory viral infection was 4.1 (95 % CI 2.0–8.5) for AECOPD as compared with stable COPD. Rhinovirus was the most common virus and with a weighted prevalence of 14.8 % (95 % CI 13.3–16.5). Respiratory viruses probably are important etiological agents in patients with AECOPD as compared with the stable COPD patients. This result would help to provide better strategies for management of AECOPD and health-care planning.     

Predictors of mortality of patients with acute respiratory failure secondary to chronic obstructive pulmonary disease admitted to an intensive care unit: A one year study

Background

Patients with acute exacerbation of chronic obstructive pulmonary disease (COPD) commonly require hospitalization and admission to intensive care unit (ICU). It is useful to identify patients at the time of admission who are likely to have poor outcome. This study was carried out to define the predictors of mortality in patients with acute exacerbation of COPD and to device a scoring system using the baseline physiological variables for prognosticating these patients.

Methods

Eighty-two patients with acute respiratory failure secondary to COPD admitted to medical ICU over a one-year period were included. Clinical and demographic profile at the time of admission to ICU including APACHE II score and Glasgow coma scale were recorded at the time of admission to ICU. In addition, acid base disorders, renal functions, liver functions and serum albumin, were recorded at the time of presentation. Primary outcome measure was hospital mortality.

Results

Invasive ventilation was required in 69 patients (84.1%). Fifty-two patients survived to hospital discharge (63.4%). APACHE II score at the time of admission to ICU {odds ratio (95 % CI): 1.32 (1.138–1.532); p < 0.001} and serum albumin (done within 24 hours of admission) {odds ratio (95 % CI): 0.114 (0.03-0.432); p = 0.001}. An equation, constructed using the adjusted odds ratio for the two parameters, had an area under the ROC curve of 91.3%. For the choice of cut-off, sensitivity, specificity, positive and negative predictive value for predicting outcome was 90%, 86.5%, 79.4% and 93.7%.

Conclusion

APACHE II score at admission and SA levels with in 24 hrs after admission are independent predictors of mortality for patients with COPD admitted to ICU. The equation derived from these two parameters is useful for predicting outcome of these patients.